Spark Therapeutics to Participate in Multiple Upcoming Conferences
September 21 2016 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company seeking to transform the lives of patients with
debilitating genetic diseases by developing potential one-time,
life-altering treatments, announced today that members of company
management or key investigators will present at the following
upcoming conferences:
2016 Leerink Partners Rare Disease Roundtable Series, at the
Lotte NY Palace in New York City
- Stephen Webster, chief financial officer, will participate in
the Rare Disease and Immuno-Oncology roundtable discussion on
Wednesday, Sept. 28, at 3:40 p.m. (EDT)
XII International Conference of the Argentinian Society of
Retina and Vitreous, at the Hotel Arakur in Ushuaia, Argentina
- Paolo Falabella, M.D., Medical Affairs Ophthalmic Lead, will
talk about “Investigational ocular gene therapy for RPE65-mediated
retinal dystrophy” on Monday, Oct. 3, at 12:50 p.m. (EDT)
2016 European Association for Vision and Eye Research (EVER)
Congress, at the Acropolis Convention Center in Nice, France
- Bart Leroy, M.D., director of the Ophthalmic Genetics and
Retinal Degenerations clinics in the Division of Ophthalmology and
Center for Cellular and Molecular Therapeutics at The Children's
Hospital of Philadelphia, will speak about “Current gene therapy
trials for inherited retinal disorders” on Wednesday, Oct. 5, at
5:56 p.m. (CET). Dr. Leroy is an investigator in the clinical
development program for voretigene neparvovec, Spark Therapeutics’
lead investigational gene therapy for RPE-65 mediated inherited
retinal disease.
2016 NORD Rare Diseases & Orphan Products Breakthrough
Summit 2016, at the Hyatt Regency Crystal City in Arlington, VA
- Jeffrey D. Marrazzo, chief executive officer, will participate
in the "Potential Advances Through Genetic Innovation" panel
discussion, on Monday, Oct. 17, at 11 a.m. (EDT)
MIT Review emTech Conference, at the MIT Media Lab in Boston
- Katherine High, M.D., president and chief scientific officer,
will speak about “Gene Therapy - A New Era of Medicine” on Tuesday,
Oct. 18, at 11 a.m. (EDT)
2016 European Society of Gene & Cell Therapy (ESGCT), at the
Palazzo dei Congressi e degli Affari in Florence, Italy
- Katherine High, M.D., president and chief scientific officer,
will participate in the In vivo Gene Therapy session on Thursday,
Oct. 20, at 10:30 a.m. (CET)
Additionally, company representatives will attend the following
conference for one-on-one meetings:
- Jefferies Gene Editing/Gene Therapy Summit, at the Jefferies
Conference Center, in New York City on Tuesday, Oct. 11
About Spark TherapeuticsSpark Therapeutics, a
fully integrated gene therapy company, is seeking to transform the
lives of patients with debilitating genetic diseases by developing
potential one-time, life-altering treatments. Spark Therapeutics’
validated gene therapy platform is being applied to a range of
clinical and preclinical programs addressing serious genetic
diseases, including inherited retinal diseases, liver-associated
diseases, such as hemophilia, and neurodegenerative diseases.
Spark Therapeutics’ validated platform has successfully
delivered proof-of-concept data with investigational gene therapies
in the eye and liver. Spark Therapeutics’ most advanced product
candidate, voretigene neparvovec (formerly referred to as
SPK-RPE65), which has received both breakthrough therapy and orphan
product designations, reported positive top-line results from a
pivotal Phase 3 clinical trial for the treatment of a rare blinding
condition. Spark Therapeutics’ hemophilia franchise has two lead
assets: SPK-9001 in a Phase 1/2 trial for hemophilia B
and SPK-8011, a preclinical candidate for hemophilia A. To
learn more, please visit www.sparktx.com.
Spark Therapeutics Corporate Contacts
Stephen W. Webster
Chief Financial Officer
Daniel Faga
Chief Business Officer
(855) SPARKTX (1-855-772-7589)
Media Contact:
Dan Quinn
Ten Bridge Communications
(781) 475-7974
dan@tenbridgecommunications.com
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Apr 2023 to Apr 2024